通过可电离脂肪体mRNA治疗高尿血症的阿塔维斯策略
Mengjie Zhang1, Abid Hussain1, Bo Hu1
1School of Life Science, Advanced Research Institute of Multidisciplinary Science, Aerospace Center Hospital, School of Medical Technology, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, Beijing, China.
Nature communications
|July 31, 2024
概括
这项研究引入了一种新的mRNA疗法 (mUox@iLAND),通过恢复尿酸氧化酶 (Uox) 功能来治疗高尿素血症. 这种方法有效地降低了小鼠的血清尿酸 (SUA) 水平,为治疗痛风和相关疾病提供了潜在的治疗机会.
科学领域:
- 生物化学 生化学
- 分子生物学分子生物学
- 基因治疗 基因治疗
背景情况:
- 血清尿酸 (SUA) 升高的特征是高尿血,这与痛风,高血压,糖尿病和心血管疾病有关.
- 与大多数哺乳动物不同,人类和猿类缺乏功能性尿酸氧化酶 (Uox),这是负责代谢尿酸 (UA) 的酶.
- 进化过程中Uox功能的丧失有助于人类高尿素血的流行.
研究的目的:
- 通过重新引入内源性Uox活性来开发超尿血症的新疗法.
- 评估基于mRNA的药物在治疗高尿血症时的疗效和安全性.
- 调查这种方法在预防与高SUA水平相关的疾病方面的潜力.
主要方法:
- 开发一种mRNA剂 (mUox@iLAND) 使用可离子化脂质纳米颗粒用于肝细胞输送.
- 在体外评估转染效率和Uox蛋白表达.
- 在小鼠模型中,mUox@iLAND在体内给药以测量SUA水平,并通过代谢学证实有效性.
- 在动物模型中评估安全概况.
主要成果:
- mUox@iLAND在体外证明了有效的转染和Uox蛋白的表达.
- 在两种小鼠模型中,单剂量mUox@iLAND在几周内显著降低了SUA水平.
- 代谢学分析证实了SUA的减少.
- 在体内,mRNA药物表现出良好的安全性.
结论:
- 开发的mRNA剂 (mUox@iLAND) 显示出作为治疗高尿血症的治疗策略的巨大潜力.
- 这种方法为恢复内源性Uox活性提供了一种有希望的方法,以管理高水平的SUA.
- 治疗也可能有助于预防相关的代谢和心血管疾病.
相关概念视频
Drug Metabolism: Phase II Reactions
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
Enhanced Elimination of Poison
Poison can be effectively removed from the gastrointestinal (GI) tract through various decontamination procedures.
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...


